|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM127156968 |
| 003 |
DE-627 |
| 005 |
20250204063445.0 |
| 007 |
tu |
| 008 |
231222s2003 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0424.xml
|
| 035 |
|
|
|a (DE-627)NLM127156968
|
| 035 |
|
|
|a (NLM)12968483
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Segawa, Naoki
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Prostate cancer detection by prostate-specific antigen-related parameters
|
| 264 |
|
1 |
|c 2003
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.09.2003
|
| 500 |
|
|
|a Date Revised 17.11.2004
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Total serum prostate-specific antigen (PSA) levels, free-to-total PSA ratio (F/T ratio) and PSA density (PSAD) were compared to clarify the clinical significance of these parameters in the diagnosis of prostate cancer (CaP) with intermediate PSA concentrations (4-10 ng/ml). PSAD and F/T ratio were obtained during the period from May 1999 to April 2001 from 43 patients with serum PSA concentrations of 4-10 ng/ml who underwent ultrasound-guided systematic sextant biopsies. PSAD was compared with total serum PSA and F/T ratio via receiver operating characteristic (ROC) curves for diagnosis of CaP. Diagnosis of CaP and non-CaP was made in 12 (27.9%) and 31 (72.1%) of the 43 patients, respectively. Mean serum PSA, PSA density and F/T ratio were 7.308 +/- 0.636 ng/ml, 0.271 +/- 0.039 ng/ml/cm3 and 16.225 +/- 4.911% in patients with CaP and 6.300 +/- 0.289 ng/ml, 0.178 +/- 0.020 ng/ml/cm3 and 15.213 +/- 0.980% in those with non-CaP, respectively. The ROC curve analysis demonstrated that PSAD predicted the biopsy outcome significantly better than F/T ratio and total PSA in all 43 patients (p < 0.05). In distinguishing CaP patients, the cutoff value of 0.16 ng/ml/cm3 for PSAD yielded a specificity level of 71.0% at a sensitivity level of 83.3%. Our study revealed that PSAD is a significant predictor in distinguishing CaP from non-CaP in Japanese men
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Prostate-Specific Antigen
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.77
|2 NLM
|
| 700 |
1 |
|
|a Gohji, Kazuo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Iwamoto, Yusaku
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ueda, Haruhiko
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Katsuoka, Yoji
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 49(2003), 7 vom: 11. Juli, Seite 405-10
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:49
|g year:2003
|g number:7
|g day:11
|g month:07
|g pages:405-10
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 49
|j 2003
|e 7
|b 11
|c 07
|h 405-10
|